CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Detroit, Michigan, United States and 84 other locations
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Detroit, Michigan, United States and 63 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Detroit, Michigan, United States and 50 other locations
This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as...
Phase 3
Detroit, Michigan, United States and 30 other locations
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Phase 1
Ann Arbor, Michigan, United States and 29 other locations
type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...
Phase 1, Phase 2
Farmington Hills, Michigan, United States of America and 123 other locations
locally advanced or metastatic disease.In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors...
Phase 1
Detroit, Michigan, United States and 36 other locations
the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...
Phase 1, Phase 2
Detroit, Michigan, United States and 30 other locations
or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung...
Phase 3
Farmington Hills, Michigan, United States and 31 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Detroit, Michigan, United States and 210 other locations
Clinical trials
Research sites
Resources
Legal